Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.
The FDA recently deemed corrective actions to three devices as Class 1, reserved for situations in which "there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
New Jersey-based pharma giant Johnson & Johnson already has a presence in Florida, but it's about to get bigger--by 500 jobs.
Johnson & Johnson is joining forces with hardware manufacturing company PCH to launch a consumer-health focused hardware startup incubator, building on J&J's commitment to investing in early-stage companies to spur med tech innovation.
Johnson & Johnson and Genmab have played another card in their deck of data on the multiple myeloma blockbuster contender daratumumab, spelling out some encouraging data that's now being used to help persuade the FDA to deliver a fast marketing approval.
Johnson & Johnson is trying a new tack on the old "Talk to your doctor" advice. With a new campaign for its HIV drug Prezcobix, the company is urging potential patients to snap a photo and send it to their physicians to see if the drug is right for them.
With approvals in the U.S and Europe expected soon, it looked like Takeda would have time to get its new multiple myeloma treatment into the market before patents fell off of blockbuster Velcade in 2022. But CEO Christophe Weber may need to plot a new strategy after a federal judge overturned a key patent, putting the Japanese drugmaker's drug vulnerable to generics 5 years early.
Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.
Johnson & Johnson's Animas is working with Type 1 diabetes technology nonprofit Tidepool to use its open-source software platform to assemble and analyze data for diabetes device, fitness and food tracking. The news comes in the wake of announcements in recent months from major diabetes device makers, including Medtronic, DexCom and Insulet, that they are partnering with startup Glooko to similarly enable connectivity as well as data transmission and analysis.
The Competition Commission of India said in a Tweet that it has approved the formation of Johnson & Johnson's joint venture with Google in surgical robotics.